Fundraising Fox

Navitor Pharmaceuticals

Cambridge, US · Founded 2010 · Delaware corporation · 6 known investors

navitorpharma.com ↗
Biotech

Founders & leadership

RL
Rick LundbergExecutive
GP
George P. VlasukExecutive
GV
George VlasukNamed on SEC filing

Board

JFJean-Francois Formela
Jean-Francois FormelainBoard directorPartner at Atlas Venture
ACAlan Crane
Alan CraneBoard directorEntrepreneur Partner at Polaris Partners
MN
Marian NakadaBoard director
BGBrian Gallagher
Brian Gallagherin𝕏Board of Directors2014–2018Partner at SR One Capital Management
VP
Vinzenz PloererBoard director
DM
David MaddenBoard director
PF
Paul FriedmanBoard director
BB
Barry BurgdorfBoard director

Investors · 6

age1San Francisco · $500K – $4M
Brace PharmaAtlanta
Sanofi VenturesCambridge · $5M
Atlas Venturereported · 2 sourcesCambridge · $500K – $1Mvia Kevin Bitterman · board
Polaris PartnersreportedBoston · $500K – $5Mvia Alan Crane · board
SR One Capital ManagementreportedRedwood Cityvia Rajeev Dadoo · board

Reported raises · per SEC filings

Form D private placements

$68.2M disclosed across 5 rounds · 2013–2020

▶$20.2MraisedMay 2020 · 19 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Rajeev DadooDirector
  • David MaddenDirector
  • Georg VlasukDirector
  • Kevin BittermanDirector
  • John CreecyExecutive Officer, Director
  • Marian NakadaDirector
  • Vinzenz PloererDirector
  • Alan CraneDirector
  • Richard LundbergExecutive Officer
  • Thomas HughesExecutive Officer
Offering amount
$20.2M
Amount sold
$20.2M
First sale
Apr 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.3MraisedJan 2019 · 12 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Alan CraneDirector
  • David MaddenDirector
  • George P. VlasukExecutive Officer, Director
  • Rick LundbergExecutive Officer
  • Kevin BittermanDirector
  • Rajeev DadooDirector
  • Marian Nakada, Ph.D.Director
  • Thomas HughesExecutive Officer, Director
  • Vinzenz PloererDirector
  • John CreecyDirector
Offering amount
$11.3M
Amount sold
$11.3M
First sale
Dec 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.3MraisedMar 2018 · 12 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • George P. VlasukExecutive Officer, Director
  • Vinzenz PloererDirector
  • John CreecyDirector
  • David MaddenDirector
  • Alan CraneDirector
  • Brian Gallagher, Ph.D.Director
  • Rick LundbergExecutive Officer
  • Paul Friedman, M.D.Director
  • Marian Nakada, Ph.D.Director
  • Kevin BittermanDirector
Offering amount
$25M
Amount sold
$11.3M
First sale
Mar 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12MraisedDec 2015 · 11 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jean-Francois FormelaDirector
  • Rick LundbergExecutive Officer
  • Alan CraneDirector
  • David MaddenDirector
  • Marian NakadaDirector
  • Brian GallagherDirector
  • Paul FriedmanDirector
  • George P. VlasukExecutive Officer, Director
  • Barry BurgdorfDirector
  • Vinzenz PloererDirector
Offering amount
$33.3M
Amount sold
$12M
First sale
Dec 2015
Incorporated
Corporation, Delaware, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13.5MraisedAug 2014 · 10 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Rick LundbergExecutive Officer
  • George VlasukExecutive Officer, Director
  • Brian GallagherDirector
  • Alan CraneDirector
  • Marian NakadaDirector
  • Jean-Francois FormelaDirector
Offering amount
$23.5M
Amount sold
$13.5M
First sale
Sep 2013
Incorporated
Corporation, Delaware, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Navitor Pharmaceuticals went on to found or lead other companies.

Alan CraneDirectorFounded Dyno TherapeuticsKevin BittermanBoard of DirectorsFounded Editas Medicine

In the news

Cambridge Massachusetts based Navitor Pharmaceuticals is raising $20,186,771.00 in New Equity Investment. - intelligence360intelligence360.news · May 2020Navitor Pharmaceuticals Commences Phase 1 Clinical Evaluation of NV-5138, a Novel mTORC1 Activator in Patients with Treatment-Resistant Depression - BioSpacebiospace.com · Jan 2019Navitor Pharmaceuticals Completes $33M Series B Financing - FinSMEsfinsmes.com · Dec 2015Navitor Pharmaceuticals Launches with $23.5 Million Series A Financing for Novel Drug Discovery Targeting Cellular Nutrient Signaling to Treat Chronic Diseases and Rare Disorders | Fierce Biotechfiercebiotech.com · Jun 2014Navitor Pharmaceuticals Raises $23.5M Series A Financing - FinSMEsfinsmes.com · Jun 2014

Frequently asked questions

Who are Navitor Pharmaceuticals's investors?
Navitor Pharmaceuticals's investors include age1, Brace Pharma, Sanofi Ventures, Atlas Venture, Polaris Partners, SR One Capital Management.
How much funding has Navitor Pharmaceuticals raised?
Navitor Pharmaceuticals has disclosed $68.2M raised across 5 rounds.
Where is Navitor Pharmaceuticals headquartered?
Navitor Pharmaceuticals is headquartered in Cambridge, US.